BioTuesdays

Tag - William Blair

Arcellx
Markets

WB starts Arcellx at OP; fair value estimate $40

William Blair initiated coverage of Arcellx (NASDAQ:ACLX) with an “outperform” rating and fair value estimate of $40. The stock closed at $16.94 on Feb. 28. Arcellx’s next-generation cell therapy platform is founded on...

March 1, 2022
Bionomics
Markets

Analysts start Bionomics at OW, OP

Analysts for Cantor Fitzgerald and William Blair launched coverage of Bionomics (NASDAQ:BNOX) with “overweight” and “outperform” ratings, respectively. Australia-based Bionomics is a clinical-stage biopharmaceutical...

January 10, 2022
Nkarta Therapeutics
Markets

WB starts Nkarta at OP; fair-value estimate $35

William Blair launched coverage of Nkarta (NASDAQ:NKTX) with an “outperform” rating and fair-value estimate of $35. The stock closed at $14.27 on Jan. 5. Nkarta is developing allogeneic chimeric antigen receptor (CAR)...

January 6, 2022
Cardiff Oncology
Markets

WB starts Cardiff Oncology at outperform

William Blair initiated coverage of Cardiff Oncology (NASDAQ:CRDF) with an “outperform” rating. The stock closed at $6.43 on Jan.4. Cardiff is advancing on vansertib, a specific PLK1 inhibitor, which “we view as a...

January 5, 2022
Generation Bio
Markets

WB cuts Generation Bio to market perform

William Blair downgraded Generation Bio (NASDAQ:GBIO) to “market perform,” citing variability in a non-human primate study in Factor VIII production for its hemophilia program.  In mid-morning trading, the stock was...

December 14, 2021
AugMedix
Markets

WB starts Augmedix at OP

William Blair launched coverage of Augmedix (NASDAQ:AUGX) with an “outperform” rating. The stock closed at $3.63 on Oct. 29. Augmedix provides a virtual medical documentation and live clinical support service, which...

November 1, 2021
Tempest Therapeutics
Markets

WB starts Tempest Therapeutics at OP

William Blair initiated coverage of Tempest Therapeutics (NASDAQ:TPST) with an “outperform” rating based on the potential of the company’s three first-in-class programs, including the dual EP2/EP4 antagonist, TPST-1495...

October 21, 2021
Jasper Therapeutics
Markets

WB starts Jasper Therapeutics at OP

William Blair launched coverage of Jasper Therapeutics (NASDAQ:JSPR) with an “outperform” rating based on the potential for JSP191 to transform the bone marrow transplant field through safer and more-effective...

October 21, 2021